KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) Enterprise Value (2018 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Enterprise Value for 7 consecutive years, with -$278.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Enterprise Value rose 20.11% year-over-year to -$278.6 million, compared with a TTM value of -$278.6 million through Dec 2025, up 22.28%, and an annual FY2024 reading of -$358.5 million, down 2.28% over the prior year.
  • Enterprise Value was -$278.6 million for Q3 2025 at Aurinia Pharmaceuticals, up from -$315.1 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$278.6 million in Q3 2025 and bottomed at -$466.1 million in Q4 2021.
  • Average Enterprise Value over 5 years is -$350.6 million, with a median of -$348.7 million recorded in 2024.
  • The sharpest move saw Enterprise Value tumbled 31.51% in 2022, then increased 20.11% in 2025.
  • Year by year, Enterprise Value stood at -$466.1 million in 2021, then grew by 16.45% to -$389.4 million in 2022, then increased by 9.99% to -$350.5 million in 2023, then decreased by 2.28% to -$358.5 million in 2024, then increased by 22.28% to -$278.6 million in 2025.
  • Business Quant data shows Enterprise Value for AUPH at -$278.6 million in Q3 2025, -$315.1 million in Q2 2025, and -$312.9 million in Q1 2025.